- Conditions
- Stage I Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7, Stage I Nasopharyngeal Undifferentiated Carcinoma AJCC v7, Stage II Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7, Stage II Nasopharyngeal Undifferentiated Carcinoma AJCC v7, Stage III Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7, Stage III Nasopharyngeal Undifferentiated Carcinoma AJCC v7, Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7, Stage IV Nasopharyngeal Undifferentiated Carcinoma AJCC v7
- Interventions
- Amifostine, Cisplatin, Fluorouracil, Laboratory Biomarker Analysis, Radiation Therapy
- Drug · Other · Radiation
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 18 Years
- Enrollment
- 111 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2022
- U.S. locations
- 101
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 74 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 889–912
of 2,553
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Non-small Cell Lung Cancer (NSCLC)
- Interventions
- Datopotamab deruxtecan (Dato-DXd), Docetaxel
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 51
- States / cities
- Chandler, Arizona • Gilbert, Arizona • Goodyear, Arizona + 47 more
- Conditions
- Breast Cancer
- Interventions
- Palbociclib, Standard Adjuvant Endocrine Therapy
- Drug
- Lead sponsor
- Alliance Foundation Trials, LLC.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5,796 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2028
- U.S. locations
- 192
- States / cities
- Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 138 more
- Conditions
- End Stage Renal Disease, Anemia
- Interventions
- Roxadustat, Epoetin Alfa, Placebo
- Drug · Other
- Lead sponsor
- Kyntra Bio
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 161 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 25
- States / cities
- Tempe, Arizona • Pine Bluff, Arkansas • Azusa, California + 22 more
- Conditions
- Breast Cancer, Breast Neoplasms
- Interventions
- Disitamab vedotin
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 128
- States / cities
- Daphne, Alabama • Foley, Alabama • Mobile, Alabama + 103 more
- Conditions
- Neoplasms, Non-small-cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma, Colorectal Carcinoma, Ovarian Carcinoma
- Interventions
- PF-07826390, sasanlimab, SOC (anti-PD-1 + platinum -based chemo)
- Drug · Biological · Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 8
- States / cities
- Beverly Hills, California • Fort Myers, Florida • Orlando, Florida + 4 more
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Memantine Hydrochloride, Bevacizumab, Atezolizumab
- Drug
- Lead sponsor
- Inova Health Care Services
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 2
- States / cities
- Fairfax, Virginia • Falls Church, Virginia
- Conditions
- Osteosarcoma
- Interventions
- Cytology Specimen Collection Procedure
- Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Not listed
- Enrollment
- 957 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2023
- U.S. locations
- 160
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 116 more
- Conditions
- Abdominal Aortic Aneurysm (AAA)
- Interventions
- Nellix System
- Device
- Lead sponsor
- Endologix
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 333 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2022
- U.S. locations
- 27
- States / cities
- Tucson, Arizona • San Diego, California • New Haven, Connecticut + 23 more
- Conditions
- NSCLC
- Interventions
- ctDNA, tumor NGS
- Diagnostic Test
- Lead sponsor
- Lung Cancer Mutation Consortium
- Network
- Eligibility
- Not listed
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 21
- States / cities
- Davis, California • Los Angeles, California • Orange, California + 13 more
- Conditions
- Solid Tumor and Hematologic Malignancies
- Interventions
- MEK162
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 68
- States / cities
- Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 57 more
- Conditions
- Alzheimer Disease, Cognitive Impairment, Mild Cognitive Impairment, Dementia, Mild, Dementia Moderate, Dementia Alzheimers, Dementia of Alzheimer Type, AD
- Interventions
- Sensory Stimulation System (GS120) - Active
- Device
- Lead sponsor
- Cognito Therapeutics, Inc.
- Industry
- Eligibility
- 50 Years to 92 Years
- Enrollment
- 402 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 53
- States / cities
- Phoenix, Arizona • Sun City, Arizona • Anaheim, California + 48 more
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- capmatinib
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 6
- States / cities
- La Jolla, California • Sacramento, California • Fairfax, Virginia
- Conditions
- Locally Advanced or Metastatic Solid Tumors, Esophageal Squamous Cell Cancer, Head and Neck Squamous Cell Cancer, NSCLC (Non-small Cell Lung Cancer), Hormone-receptor-positive Breast Cancer, Triple Negative Breast Cancer (TNBC)
- Interventions
- XB010, Pembrolizumab
- Drug
- Lead sponsor
- Exelixis
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 396 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 16
- States / cities
- Irvine, California • Los Angeles, California • Washington D.C., District of Columbia + 12 more
- Conditions
- Crohn Disease
- Interventions
- Ustekinumab, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 9
- States / cities
- Wilmington, Delaware • Atlanta, Georgia • Rochester, Minnesota + 6 more
- Conditions
- B-Cell Non-Hodgkin Lymphoma, Relapsed B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma
- Interventions
- Loncastuximab Tesirine, Polatuzumab Vedotin, Glofitamab, Mosunetuzumab, Obinutuzumab
- Drug
- Lead sponsor
- ADC Therapeutics S.A.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 154 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 24
- States / cities
- Clovis, California • San Diego, California • Miami, Florida + 18 more
- Conditions
- Alzheimer's Disease
- Interventions
- Remternetug, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 55 Years to 80 Years
- Enrollment
- 1,400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 123
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 108 more
- Conditions
- Hepatitis C, Chronic
- Interventions
- Copegus, Pegasys, RO4588161
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 516 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 30
- States / cities
- Phoenix, Arizona • La Jolla, California • Long Beach, California + 26 more
- Conditions
- Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma
- Interventions
- Cemiplimab
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 97 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 9
- States / cities
- Phoenix, Arizona • San Diego, California • Delray Beach, Florida + 6 more
- Conditions
- Chronic Renal Failure, Chronic Kidney Disease, Anemia
- Interventions
- peginesatide, Darbepoetin alfa
- Drug
- Lead sponsor
- Affymax
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 493 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 42
- States / cities
- Phoenix, Arizona • Fayetteville, Arkansas • Fountain Valley, California + 38 more
- Conditions
- Leukemia
- Interventions
- filgrastim, asparaginase, cyclophosphamide, cytarabine, daunorubicin hydrochloride, dexamethasone, etoposide, idarubicin, leucovorin calcium, mercaptopurine, methotrexate, prednisone, vincristine sulfate, radiation therapy
- Biological · Drug · Radiation
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 17 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2007
- U.S. locations
- 51
- States / cities
- Tucson, Arizona • Palo Alto, California • Sacramento, California + 44 more
- Conditions
- Fabry Disease
- Interventions
- ST-920
- Biological
- Lead sponsor
- Sangamo Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 9
- States / cities
- Irvine, California • Tampa, Florida • Atlanta, Georgia + 6 more
- Conditions
- Heart Failure
- Interventions
- Not listed
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2034
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Falls Church, Virginia
- Conditions
- Advanced Breast Cancer, Metastatic Breast Cancer
- Interventions
- non-interventional
- Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,285 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 301
- States / cities
- Alabaster, Alabama • Bessemer, Alabama • Birmingham, Alabama + 224 more